World-class research and a commitment to cutting-edge science has made a global icon of CRMI thanks to which the regional life science industry is surging forward with new vigor.

China Regenerative Medicine International Ltd (“CRMI”), listed on The Stock Exchange of Hong Kong Ltd on 18 July 2001 (Stock Code: 8158.HK), is China’s first high-end new-technology enterprise principally engaged in research and development, production and sales of tissue engineering and regenerative medicine products.

After unremitting efforts over decades, the Group has evolved into a tissue engineering pioneer and has successfully industrialized regenerative medicine in the PRC, as well as accomplished the research and development and commercialization platform of tissue engineering.

The Group currently focuses on four major business segments, namely tissue engineering, cell therapy, cosmetics and hospital management.

In the realms of life science, the Group has undertaken various national pivotal projects including The National High Technology Research and Development Program of China (863 Program) and The National Basic Research Program (973 Program). The Group has also received many significant scientific awards including the First Class Award of the National Science and Technology Progress Award.

Giant Strides

In July 2001, the Group lists on the Growth Enterprise Market of The Stock Exchange of Hong Kong Ltd (Stock code: 8158).

In October 2008, the Group commenced R&D in tissue engineering via majority interest acquisition of in Shaanxi Aierfu ActivTissue Engineering Co., Ltd.

In October 2013, the Group’s tissue engineered skin with living human cells “ActivSkin” obtained medical device good manufacturing practice inspection result notice from China Food and Drug Administration.

In December 2014, the Group collaborated with the University of Oxford to establish the “CRMI Technology Centre at the University of Oxford” where the Group has designated it as its core R&D institution. Following the Rolls-Royce Group and Invensys Group, the Group is the third enterprise to set up a technology and R & D centre with the University of Oxford.”

Surging Forward

Medicine industry in the PRC has experienced much improvement these years. The government has released several related policies including Healthy China 2030 in October 2016. The 19th National Congress of the Communist Party has also rolled out “Healthy China Strategy” which will help to upgrade the health and medical level in the PRC.

Headquartered in Hong Kong, the Group has seven modernized manufacturing facilities in Xi’an, Shenzhen, Suzhou, Tianjin, Changzhou and Hong Kong.

A company spokesperson said, “we work closely with academy institutes and government bodies in the PRC. The Group maintains solid collaboration with leading research institutions, including Versitech Ltd, The 4th Military Medical University, and Xi’an Tissue Engineering Technology Research Center. We also collaborate with well-known hospitals on clinical research, including PLA General Hospital, PLA 304 Hospital, Beijing Tongren Hospital and Wenzhou Medical College Hospital.”

Fresh Focus

The Group currently focuses on four major business segments, namely tissue engineering, cell therapy, cosmetics and hospital management. The Group’s product lines are aimed at a complete industry chain to create synergy at the Group’s businesses. For example, the Group’s iconic products as “Acornea” and “ActivSkin” have amply used the sophisticated technology and know-how on its tissue engineering business.

The Group is building one-stop comprehensive cell therapy infrastructures by leveraging on ‘CRMI Technology Centre at the University of Oxford’.

HK International Regenerative Centre Ltd under the Group is the first cell preparation and storage centre in Asia and the first large-scale and comprehensive base for precision medicine in Hong Kong to providing precise, well-rounded and customized anti-aging aesthetic medicine and health management services.”

The Group will also enhance the sales and marketing efforts in respect of tissue engineering, cell therapy, cosmetic and hospital management for enhancing the operational and financial results.

The Group will strive to capture new cooperation with operation institutions in the PRC. The Group will continuously embark on three important elements including medicine technology, market share and brand recognition to boost sustainable sales of the Group’s products.

For additional information, please visit

Hong Kong’s Business Leaders share market and interest intelligence in the pages of HKMVC 2018